Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2014

01.12.2014 | Erratum

Erratum to: Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours

verfasst von: Brigid C. Browne, Alex J. Eustace, Susan Kennedy, Neil A. O’Brien, Kasper Pedersen, Martina S. J. McDermott, Annemarie Larkin, Jo Ballot, Thamir Mahgoub, Francesco Sclafani, Stephen Madden, John Kennedy, Michael J. Duffy, John Crown, Norma O’Donovan

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Excerpt

In the original publication, the authors stated that “high levels of IGF1R and pIGF1R were associated with higher IC50 values for NVP-AEW541, with p values approaching statistical significance (IGF1R: P = 0.053; pIGF1R: P = 0.078)”. This statement should read as “high levels of IGF1R and pIGF1R were associated with lower IC50 values for NVP-AEW541”. Consequently high IGF1R and pIGF1R levels are weakly predictive of sensitivity to NVP-AEW541. These updated data have no significant effect on any of the other statistical correlations listed in the article. …
Metadaten
Titel
Erratum to: Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours
verfasst von
Brigid C. Browne
Alex J. Eustace
Susan Kennedy
Neil A. O’Brien
Kasper Pedersen
Martina S. J. McDermott
Annemarie Larkin
Jo Ballot
Thamir Mahgoub
Francesco Sclafani
Stephen Madden
John Kennedy
Michael J. Duffy
John Crown
Norma O’Donovan
Publikationsdatum
01.12.2014
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2014
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-014-3176-3

Weitere Artikel der Ausgabe 3/2014

Breast Cancer Research and Treatment 3/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.